On September 16, 2021, Rhaeos Inc., a medical device company focused on the development of a device to rapidly monitor shunt function in people with hydrocephalus, announced that they were awarded a $4 million grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program. The program is run through National Institute of Neurological Disorders and Stroke (NINDS) and is designed to accelerate the development of new medical devices.
Rhaeos will use the funding to further the development of FlowSense™, a wireless noninvasive device that assesses CSF shunt function. This flexible sensor is placed on the skin directly over the shunt tubing and sends data related to CSF flow to a mobile app for review by a doctor. FlowSense™ is not yet FDA approved, but the ultimate goal of this work is to bring the technology to the clinic to improve care for hydrocephalus patients.
Concurrent with the work to expand the functionality of their sensor, Rhaeos is currently conducting a clinical trial to assess the diagnostic performance of FlowSense™ in patients experiencing shunt failure symptoms. The study is enrolling at three hospitals, two in Illinois and one in California.
View the Rhaeos press release.
Learn more about the clinical trial.
Read our 2020 interview with Rhaeos CEO Anna Lisa Somera.